JP2009537544A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009537544A5 JP2009537544A5 JP2009511063A JP2009511063A JP2009537544A5 JP 2009537544 A5 JP2009537544 A5 JP 2009537544A5 JP 2009511063 A JP2009511063 A JP 2009511063A JP 2009511063 A JP2009511063 A JP 2009511063A JP 2009537544 A5 JP2009537544 A5 JP 2009537544A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- alkyl
- salt
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 135
- 150000001875 compounds Chemical class 0.000 claims description 106
- 125000000217 alkyl group Chemical group 0.000 claims description 73
- 150000003839 salts Chemical group 0.000 claims description 40
- 125000001188 haloalkyl group Chemical group 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- 208000035475 disorder Diseases 0.000 claims description 32
- 125000005843 halogen group Chemical group 0.000 claims description 30
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 28
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 28
- 125000003545 alkoxy group Chemical group 0.000 claims description 26
- 208000028017 Psychotic disease Diseases 0.000 claims description 24
- 125000003342 alkenyl group Chemical group 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 24
- 125000000304 alkynyl group Chemical group 0.000 claims description 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 201000000980 schizophrenia Diseases 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 12
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 12
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 9
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 9
- 150000003003 phosphines Chemical class 0.000 claims description 9
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 125000002252 acyl group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 7
- 206010002383 Angina Pectoris Diseases 0.000 claims description 6
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 6
- 208000020925 Bipolar disease Diseases 0.000 claims description 6
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 206010061921 Psychotic disorder due to a general medical condition Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims description 6
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims description 6
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 6
- 208000016620 Tourette disease Diseases 0.000 claims description 6
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 230000003542 behavioural effect Effects 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 230000035602 clotting Effects 0.000 claims description 6
- 208000029078 coronary artery disease Diseases 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 201000002545 drug psychosis Diseases 0.000 claims description 6
- 230000002964 excitative effect Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- 208000019116 sleep disease Diseases 0.000 claims description 6
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 150000003891 oxalate salts Chemical group 0.000 claims description 5
- -1 tri-substituted phosphine Chemical class 0.000 claims description 5
- 125000004650 C1-C8 alkynyl group Chemical group 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 230000007062 hydrolysis Effects 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 4
- 230000003301 hydrolyzing effect Effects 0.000 claims description 3
- UFXKNUCUAXZUEB-UHFFFAOYSA-N 5-chloro-1-methylpyrazole Chemical compound CN1N=CC=C1Cl UFXKNUCUAXZUEB-UHFFFAOYSA-N 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 239000012649 demethylating agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 claims description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-O morpholinium Chemical compound [H+].C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-O 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-M oxalate(1-) Chemical compound OC(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-M 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 125000004497 pyrazol-5-yl group Chemical group N1N=CC=C1* 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims 2
- 0 CCC*1CC*CC1 Chemical compound CCC*1CC*CC1 0.000 description 4
- ZTYLFNWFXGDYOB-UHFFFAOYSA-N CC1[IH]C1c(cc(cc1-c2ccn[n]2C)N)c1O Chemical compound CC1[IH]C1c(cc(cc1-c2ccn[n]2C)N)c1O ZTYLFNWFXGDYOB-UHFFFAOYSA-N 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80178906P | 2006-05-18 | 2006-05-18 | |
| US60/801,789 | 2006-05-18 | ||
| US92131807P | 2007-04-02 | 2007-04-02 | |
| US60/921,318 | 2007-04-02 | ||
| PCT/US2007/011810 WO2007136689A2 (en) | 2006-05-18 | 2007-05-17 | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009537544A JP2009537544A (ja) | 2009-10-29 |
| JP2009537544A5 true JP2009537544A5 (enExample) | 2011-06-30 |
| JP5286254B2 JP5286254B2 (ja) | 2013-09-11 |
Family
ID=38590318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009511063A Expired - Fee Related JP5286254B2 (ja) | 2006-05-18 | 2007-05-17 | ５−ｈｔ２ａセロトニンレセプター活性のモジュレーターとして有用なフェニルピラゾールの結晶形態および調製方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8481535B2 (enExample) |
| EP (2) | EP2018372B1 (enExample) |
| JP (1) | JP5286254B2 (enExample) |
| KR (1) | KR101514846B1 (enExample) |
| CN (1) | CN102827081A (enExample) |
| AU (1) | AU2007254255B2 (enExample) |
| BR (1) | BRPI0712030A2 (enExample) |
| CA (1) | CA2646081C (enExample) |
| EA (1) | EA016675B1 (enExample) |
| ES (1) | ES2543718T3 (enExample) |
| IL (2) | IL193822A (enExample) |
| MX (2) | MX349156B (enExample) |
| MY (1) | MY154962A (enExample) |
| NZ (2) | NZ594353A (enExample) |
| SG (1) | SG171681A1 (enExample) |
| WO (1) | WO2007136689A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8754238B2 (en) | 2003-07-22 | 2014-06-17 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| PE20061130A1 (es) | 2004-11-19 | 2007-01-05 | Arena Pharm Inc | Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a |
| NZ594353A (en) | 2006-05-18 | 2013-02-22 | Arena Pharm Inc | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor |
| US8148418B2 (en) | 2006-05-18 | 2012-04-03 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
| USRE45336E1 (en) | 2006-05-18 | 2015-01-13 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| JP5393677B2 (ja) | 2007-08-15 | 2014-01-22 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体 |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| HRP20180589T1 (hr) | 2008-10-28 | 2018-05-18 | Arena Pharmaceuticals, Inc. | Pripravci modulatora serotoninskog receptora 5-ht2a koji su korisni za liječenje s njim povezanih poremećaja |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| US8980891B2 (en) | 2009-12-18 | 2015-03-17 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
| JP2013525448A (ja) * | 2010-04-27 | 2013-06-20 | カルシメディカ，インク． | 細胞内カルシウムを調節する化合物 |
| RU2017145976A (ru) | 2015-06-12 | 2019-07-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна |
| TW201720439A (zh) | 2015-07-15 | 2017-06-16 | Axovant Sciences Gmbh | 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4099012A (en) | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
| DE2926517A1 (de) | 1979-06-30 | 1981-01-15 | Beiersdorf Ag | Substituierte 3-aryl-pyrazole und 5-aryl-isoxazole und verfahren zu ihrer herstellung |
| DE2928485A1 (de) | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
| US4985352A (en) | 1988-02-29 | 1991-01-15 | The Trustees Of Columbia University In The City Of New York | DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof |
| US5661024A (en) | 1989-10-31 | 1997-08-26 | Synaptic Pharmaceutical Corporation | DNA encoding a human serotonic (5-HT2) receptor and uses thereof |
| US5128351A (en) | 1990-05-04 | 1992-07-07 | American Cyanamid Company | Bis-aryl amide and urea antagonists of platelet activating factor |
| US5077409A (en) | 1990-05-04 | 1991-12-31 | American Cyanamid Company | Method of preparing bis-aryl amide and urea antagonists of platelet activating factor |
| FR2682379B1 (fr) | 1991-10-09 | 1994-02-11 | Rhone Poulenc Agrochimie | Nouveaux phenylpyrazoles fongicides. |
| FR2690440B1 (fr) | 1992-04-27 | 1995-05-19 | Rhone Poulenc Agrochimie | Arylpyrazoles fongicides. |
| DE69411176T2 (de) | 1993-08-20 | 1998-11-12 | Smithkline Beecham Plc | Amide und harnstoffderivate als 5ht1d rezeptor antagonisten |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| FR2722369B1 (fr) | 1994-07-13 | 1998-07-10 | Rhone Poulenc Agrochimie | Compositions fongicides a base de derives 3-phenyl-pyrazoles pour le traitement du materiel vegetal de multiplication, nouveaux derives 3-phenyl-pyrazoles et leurs applications fongicides |
| EP0784612A1 (en) | 1994-10-04 | 1997-07-23 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives and their use as acat-inhibitors |
| BR9607016A (pt) | 1995-02-02 | 1997-10-28 | Smithkline Beecham Plc | Derivados de indol como antagonísta de receptor 5-ht |
| EP0809492A4 (en) | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
| WO1997003967A1 (en) | 1995-07-22 | 1997-02-06 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| US6005008A (en) | 1996-02-16 | 1999-12-21 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| GB9607219D0 (en) | 1996-04-04 | 1996-06-12 | Smithkline Beecham Plc | Novel compounds |
| CA2255858C (en) | 1996-05-24 | 2007-09-11 | Neurosearch A/S | Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers |
| AU2962297A (en) | 1996-05-24 | 1998-01-05 | Neurosearch A/S | Phenyl derivatives useful as blockers of chloride channels |
| KR20000022273A (ko) | 1996-06-27 | 2000-04-25 | 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 | Il-8 수용체 길항제 |
| WO1998024785A1 (en) | 1996-12-02 | 1998-06-11 | Fujisawa Pharmaceutical Co., Ltd. | Indole-urea derivatives with 5-ht antagonist properties |
| US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
| US6541209B1 (en) | 1997-04-14 | 2003-04-01 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
| CZ295822B6 (cs) | 1997-04-22 | 2005-11-16 | Neurosearch A/S | Substituované fenylderiváty, způsob jejich přípravy a použití a farmaceutické přípravky s jejich obsahem |
| US6696475B2 (en) | 1997-04-22 | 2004-02-24 | Neurosearch A/S | Substituted phenyl derivatives, their preparation and use |
| CA2294064A1 (en) | 1997-07-29 | 1999-02-11 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| DE69835688T2 (de) | 1997-10-31 | 2007-10-04 | Aventis Pharma Ltd., West Malling | Substituierte anilide |
| IL136737A0 (en) | 1997-12-22 | 2001-06-14 | Bayer Ag | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| EP1449834A3 (en) | 1997-12-22 | 2004-12-22 | Bayer Corporation | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
| US6107324A (en) | 1998-04-14 | 2000-08-22 | Arena Pharmaceuticals Inc. | 5-HT2A receptor inverse agonists |
| US6140509A (en) | 1998-06-26 | 2000-10-31 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
| GB9816263D0 (en) | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
| CN1263733C (zh) | 1998-10-22 | 2006-07-12 | 神经研究公司 | 取代苯基衍生物,它们的制备和用途 |
| US6150393A (en) | 1998-12-18 | 2000-11-21 | Arena Pharmaceuticals, Inc. | Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors |
| UA72244C2 (en) | 1999-03-26 | 2005-02-15 | Aryl-substituted pyrazols, imidazols, oxazols, thiazols, pyrrols and their use | |
| GB9909409D0 (en) | 1999-04-24 | 1999-06-23 | Zeneca Ltd | Chemical compounds |
| WO2001021160A2 (en) | 1999-09-23 | 2001-03-29 | Axxima Pharmaceuticals Aktiengesellschaft | Carboxymide and aniline derivatives as selective inhibitors of pathogens |
| US6531291B1 (en) | 1999-11-10 | 2003-03-11 | The Trustees Of Columbia University In The City Of New York | Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof |
| EP1108720A1 (en) | 1999-12-08 | 2001-06-20 | Basf Aktiengesellschaft | Herbicidal 2-Pyrazolyl-6-Aryloxy-Pyri(mi)dines |
| FR2810979B1 (fr) | 2000-06-29 | 2002-08-23 | Adir | Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2002039987A2 (en) | 2000-11-14 | 2002-05-23 | Neurosearch A/S | Use of malaria parasite anion channel blockers for treating malaria |
| AR035521A1 (es) | 2000-12-22 | 2004-06-02 | Lundbeck & Co As H | Derivados de 3-indolina y composicion farmaceutica que los comprende |
| US20020156068A1 (en) | 2001-03-22 | 2002-10-24 | Behan Dominic P. | Anti-psychosis combination |
| DE10146119C1 (de) * | 2001-09-19 | 2002-12-19 | Krone Gmbh | Zugentlastung für einen Steckverbinder in der Kommunikations- und Datentechnik |
| CN110894196A (zh) | 2001-09-21 | 2020-03-20 | 百时美-施贵宝控股爱尔兰无限公司 | 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂 |
| WO2003062206A2 (en) | 2002-01-23 | 2003-07-31 | Arena Pharmaceuticals, Inc. | Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| WO2004028450A2 (en) | 2002-09-24 | 2004-04-08 | Arena Pharmaceuticals, Inc. | Process of making phenylpyrazoles useful as selective 5ht2a modulators and intermediates thereof |
| US7016330B2 (en) | 2002-11-08 | 2006-03-21 | Interdigital Technology Corporation | Composite channel quality estimation techniques for wireless receivers |
| WO2004058722A1 (en) * | 2002-12-24 | 2004-07-15 | Arena Pharmaceuticals, Inc. | Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a |
| WO2004071426A2 (en) | 2003-02-11 | 2004-08-26 | Kemia Inc. | Compounds for the treatment of viral infection |
| EP1611128A2 (en) | 2003-03-28 | 2006-01-04 | Pharmacia & Upjohn Company LLC | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| GB0309781D0 (en) | 2003-04-29 | 2003-06-04 | Glaxo Group Ltd | Compounds |
| US8754238B2 (en) | 2003-07-22 | 2014-06-17 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| US20050054691A1 (en) | 2003-08-29 | 2005-03-10 | St. Jude Children's Research Hospital | Carboxylesterase inhibitors |
| WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| EP1727803B3 (en) | 2004-03-23 | 2014-04-23 | Arena Pharmaceuticals, Inc. | Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl)phenyl] ureas and intermediates thereof |
| US20060014705A1 (en) | 2004-06-30 | 2006-01-19 | Howitz Konrad T | Compositions and methods for selectively activating human sirtuins |
| JP2008509982A (ja) | 2004-08-16 | 2008-04-03 | プロシディオン・リミテッド | アリール尿素誘導体 |
| US20060063754A1 (en) | 2004-09-21 | 2006-03-23 | Edgar Dale M | Methods of treating a sleep disorder |
| US7846915B2 (en) | 2004-10-20 | 2010-12-07 | Resverlogix Corporation | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| AU2005302669A1 (en) | 2004-10-27 | 2006-05-11 | Neurogen Corporation | Diaryl ureas as CB1 antagonists |
| WO2006049734A2 (en) | 2004-10-29 | 2006-05-11 | Hypnion, Inc. | Quetiapine analogs and methods of use thereof |
| PE20061130A1 (es) * | 2004-11-19 | 2007-01-05 | Arena Pharm Inc | Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a |
| GB0426313D0 (en) | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO2006060654A2 (en) | 2004-12-01 | 2006-06-08 | Divergence, Inc. | Pesticidal compositions and methods |
| US20080015223A1 (en) | 2004-12-03 | 2008-01-17 | Arena Pharmaceuticals, Inc. | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto |
| EP1831172B1 (en) | 2004-12-28 | 2009-02-18 | Council of Scientific and Industrial Research | Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors |
| WO2006076592A1 (en) | 2005-01-14 | 2006-07-20 | Cgi Pharmaceuticals, Inc. | 1,3 substituted diaryl ureas as modulators of kinase activity |
| WO2006078610A1 (en) | 2005-01-19 | 2006-07-27 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy |
| AR052886A1 (es) | 2005-01-26 | 2007-04-11 | Arena Pharm Inc | Procedimientos para preparar fenilpirazol ureas sustituidas y para la obtencion de sus intermediarios de sintesis |
| WO2006079637A1 (en) | 2005-01-27 | 2006-08-03 | Janssen Pharmaceutica N.V. | Heterocyclic tetracyclic tetrahydrofuran derivatives as 5ht2 inhibitors in the treatment of cns disorders |
| GT200600042A (es) | 2005-02-10 | 2006-09-27 | Aventis Pharma Inc | Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a |
| WO2006089871A2 (en) | 2005-02-23 | 2006-08-31 | Neurosearch A/S | Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias |
| GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| GB0505437D0 (en) | 2005-03-17 | 2005-04-20 | Merck Sharp & Dohme | Therapeutic agents |
| GB0505725D0 (en) | 2005-03-19 | 2005-04-27 | Merck Sharp & Dohme | Therapeutic agents |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| CN101208314B (zh) | 2005-04-26 | 2010-12-08 | 海普尼昂公司 | 苯并异*唑哌嗪化合物及其使用方法 |
| EP1734039A1 (en) | 2005-06-13 | 2006-12-20 | Esbatech AG | Aryl urea compounds as BETA-secretase inhibitors |
| JP5237799B2 (ja) | 2005-06-27 | 2013-07-17 | エグゼリクシス パテント カンパニー エルエルシー | ピラゾールベースのｌｘｒモジュレーター |
| US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| AR055203A1 (es) | 2005-08-31 | 2007-08-08 | Otsuka Pharma Co Ltd | Derivados de benzotiofeno con propiedades antipsicoticas |
| WO2007120600A2 (en) | 2006-04-10 | 2007-10-25 | Arena Pharmaceuticals, Inc. | 3-pyridinyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| GB0608655D0 (en) | 2006-05-03 | 2006-06-14 | Merck Sharp & Dohme | Therapeutic Treatment |
| JP2009537556A (ja) | 2006-05-18 | 2009-10-29 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５−ｈｔ２ａセロトニンレセプターに関連する障害の処置に有用な５−ｈｔ２ａセロトニンレセプターのモジュレーターとしてのアセトアミド誘導体 |
| USRE45336E1 (en) | 2006-05-18 | 2015-01-13 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
| NZ594353A (en) | 2006-05-18 | 2013-02-22 | Arena Pharm Inc | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor |
| US8148418B2 (en) | 2006-05-18 | 2012-04-03 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
| JP2010502618A (ja) | 2006-08-31 | 2010-01-28 | アリーナ ファーマシューティカルズ， インコーポレイテッド | セロトニン５−ｈｔ２ａ受容体のモジュレータとしてのベンゾフラン誘導体 |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| WO2008054748A2 (en) | 2006-10-31 | 2008-05-08 | Arena Pharmaceuticals, Inc. | Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| JP5393677B2 (ja) | 2007-08-15 | 2014-01-22 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体 |
| JP2009196349A (ja) | 2008-01-25 | 2009-09-03 | Canon Finetech Inc | バーコード印刷装置およびバーコード印刷方法 |
| US8980891B2 (en) | 2009-12-18 | 2015-03-17 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
-
2007
- 2007-05-17 NZ NZ594353A patent/NZ594353A/xx not_active IP Right Cessation
- 2007-05-17 MX MX2013007579A patent/MX349156B/es unknown
- 2007-05-17 NZ NZ571829A patent/NZ571829A/en not_active IP Right Cessation
- 2007-05-17 MY MYPI20084456A patent/MY154962A/en unknown
- 2007-05-17 AU AU2007254255A patent/AU2007254255B2/en not_active Ceased
- 2007-05-17 SG SG201103381-8A patent/SG171681A1/en unknown
- 2007-05-17 KR KR1020087028020A patent/KR101514846B1/ko not_active Expired - Fee Related
- 2007-05-17 CN CN2012102989512A patent/CN102827081A/zh active Pending
- 2007-05-17 CA CA2646081A patent/CA2646081C/en not_active Expired - Fee Related
- 2007-05-17 ES ES07794969.1T patent/ES2543718T3/es active Active
- 2007-05-17 BR BRPI0712030-3A patent/BRPI0712030A2/pt not_active Application Discontinuation
- 2007-05-17 JP JP2009511063A patent/JP5286254B2/ja not_active Expired - Fee Related
- 2007-05-17 US US12/301,212 patent/US8481535B2/en active Active
- 2007-05-17 MX MX2008014622A patent/MX2008014622A/es active IP Right Grant
- 2007-05-17 WO PCT/US2007/011810 patent/WO2007136689A2/en not_active Ceased
- 2007-05-17 EP EP20070794969 patent/EP2018372B1/en active Active
- 2007-05-17 EA EA200870544A patent/EA016675B1/ru not_active IP Right Cessation
- 2007-05-17 EP EP12162245A patent/EP2527329A1/en not_active Withdrawn
-
2008
- 2008-09-01 IL IL193822A patent/IL193822A/en active IP Right Grant
-
2012
- 2012-10-10 IL IL222340A patent/IL222340A/en active IP Right Grant
-
2013
- 2013-07-03 US US13/935,329 patent/US9199940B2/en active Active
-
2015
- 2015-10-23 US US14/921,651 patent/US9783502B2/en active Active
-
2017
- 2017-09-11 US US15/700,670 patent/US20180186748A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009537544A5 (enExample) | ||
| US8906915B2 (en) | Compounds, compositions, and methods for controlling biofilms | |
| KR102798709B1 (ko) | 항진균 화합물 제조 방법 | |
| JP4740115B2 (ja) | 置換ピラゾール | |
| EP3119745B1 (en) | Antifungal compound process | |
| KR20110098012A (ko) | 구충제 | |
| JP2009543794A5 (enExample) | ||
| WO1995007263A1 (de) | 1,2-di(het)aryl-benzimidazol derivate, deren herstellung und deren verwendung als prostazyklin-(pgi2)-mimetika | |
| JP2008542365A5 (enExample) | ||
| JP2008509896A (ja) | 保護化アミノチアゾールのフッ素化方法 | |
| JP2008508251A5 (enExample) | ||
| JP6228667B2 (ja) | 新規な抗真菌性オキソジヒドロピリジンカルボヒドラジド誘導体 | |
| KR20050119192A (ko) | 치환된 피라졸 화합물 | |
| JP2839161B2 (ja) | シクロプロピル置換アゾリルメチルカルビノール誘導体、その製造方法及び医薬としてのその用途 | |
| JP2002542233A (ja) | 置換ピリミジンの製造方法 | |
| US7705029B2 (en) | Acrylonitrile derivatives for inflammation and immune-related uses | |
| CN102603553B (zh) | 具有协同抗真菌作用的化合物及其在药学中的用途 | |
| JP2011529907A5 (ja) | イソホスホルアミドマスタードの塩およびその類似体の合成および製剤 | |
| CN107074780A (zh) | 用于生产嘧啶‑1‑醇化合物及其中间体的方法 | |
| JPS58219162A (ja) | 置換ビニルカルボン酸誘導体およびその製造法 | |
| CA2819671A1 (en) | Novel oxadiazole derivatives as sphingosine 1-phosphate (s1p) receptor modulators | |
| JP2006516588A5 (enExample) | ||
| CN109970652A (zh) | 1-甲基-3-单氟甲基吡唑-4-甲酸酰胺化合物及其制备方法、用途 | |
| JP2014511878A (ja) | スフィンゴシン−１リン酸受容体調節剤としてのフェニル二環式メチルアミン誘導体 | |
| AU2010282701A1 (en) | Selective sphingosine-1-phosphate receptor antagonists |